Back to results
US 5,859,012 AGranted
Inhibitors of farnesyl-protein transferase
AssigneeMerck & Co., Inc.
InventorsChristopher J. Dinsmore, Theresa M. Williams
Life of this patent
Estimating the term…
Abstract
The present invention is directed to piperazine-2,3-dione compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
Claims14
A compound which inhibits farnesyl-protein transferase of the formula A:
- ##STR27## wherein:
- R.sup.1a and R.sup.1b are independently selected from:
- a) hydrogen,
- b) aryl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, R.sup.10 O--, R.sup.11 S(O).sub.m --, R.sup.10 C(O)NR.sup.10 --, CN(R.sup.10).sub.2 NC(O)--, R.sup.10.sub.2 N--C(NR.sup.10)--, CN, NO.sub.2, R.sup.10 C(O)--, N.sub.3, --N(R.sup.10).sub.2, or R.sup.11 OC(O)NR.sup.10 --, and
- vc) unsubstituted or substituted C.sub.1 -C.sub.6 alkyl wherein the substitutent on the substituted C.sub.3 -C.sub.6 alkyl is selected from unsubstituted or substituted aryl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, R.sup.10 O--, R.sup.11 S(O).sub.m --, R.sup.10 C(O)NR.sup.10 --, (R.sup.10).sub.2 NC(O)--, R.sup.10.sub.2 N-- C(NR.sup.10)--, CN, R.sup.10 C(O)--, N.sub.3, --N(R.sup.10).sub.2, and R.sup.10 C(O)--NR.sup.10 --;
- R.sup.2 and R.sup.3 are independently selected from:
- H;
- unsubstituted or substituted C.sub.1-8 alkyl, unsubstituted or substituted C.sub.2-8 alkenyl, unsubstituted or substituted C.sub.2-8 alkynyl, unsubstituted or substituted aryl, ##STR28## wherein the substituted group is substituted with one or more of:
- ##STR29## and R.sup.2 and R.sup.3 are optionally attached to the same carbon atom;
- R.sup.4, R.sup.6 and R.sup.7 are independently selected from:
- H;
- C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, aryl, aroyl and arylsulfonyl, unsubstituted or substituted with:
- a) C.sub.1-4 alkoxy,
- b) aryl,
- c) halogen,
- d) HO, ##STR30## f) --SO.sub.2 R.sup.11 , or g) N(R.sup.10).sub.2 ;
- or
- R.sup.5 is selected from:
- C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl and aryl, unsubstituted or substituted with:
- a) C.sub.1-4 alkoxy,
- b) aryl,
- c) halogen,
- d) HO, ##STR31## f) --SO.sub.2 R.sup.11 or g) N(R.sup.10).sub.2 ;
- R.sup.8 is independently selected from:
- a) hydrogen,
- b) aryl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, perfluoroalkyl, F, Cl, Br, R.sup.10 O--, R.sup.11 S(O).sub.m --, R.sup.10 C(O)NR.sup.10 --, (R.sup.10).sub.2 NC(O)--, R.sup.10.sub.2 N--C(NR.sup.10)--, CN, NO.sub.2, R.sup.10 C(O)--, N.sub.3, --N(R.sup.10).sub.2, or R.sup.11 OC(O)NR.sup.10 --, and
- c) C.sub.1 -C.sub.6 alkyl unsubstituted or substituted by aryl, cyanophenyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, perfluoroalkyl, F, Cl, Br, R.sup.10 O--, R.sup.11 S(O).sub.m --, R.sup.10 C(O)NH--, (R.sup.10).sub.2 NC(O)--, R.sup.10.sub.2 N--C(NR.sup.10)--, CN, R.sup.10 C(O)--, N.sub.3, --N(R.sup.10).sub.2, or R.sup.11 OC(O)NH--;
- R.sup.9 is selected from:
- a) hydrogen,
- b) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R.sup.10 O--, R.sup.11 S(O).sub.m --, R.sup.10 C(O)NR.sup.10 --, (R.sup.10).sub.2 NC(O)--, R.sup.10.sub.2 N--C(NR.sup.10)--, CN, NO.sub.2, R.sup.10 C(O)--, N.sub.3, --N(R.sup.10).sub.2, or R.sup.11 OC(O)NR.sup.10 --, and
- c) C.sub.1 -C.sub.6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R.sup.10 O--, R.sup.10 S(O).sub.m --, R.sup.10 C(O)NR.sup.10 --, (R.sup.10).sub.2 NC(O)--, R.sup.10.sub.2 N--C(NR.sup.10)--, CN, R.sup.10 C(O)--, N.sub.3, --N(R.sup.10).sub.2, or R.sup.11 OC(O)NR.sup.10 --;
- R.sup.10 is independently selected from hydrogen, C.sub.1 -C.sub.6 alkyl, benzyl and aryl;
- R.sup.11 is independently selected from C.sub.1 -C.sub.6 alkyl and aryl;
- A.sup.1 and A.sup.2 are independently selected from:
- a bond, --CH.dbd.CH--, --C.tbd.C--, --C(O)--, --C(O)NR.sup.10 --, --NR.sup.10 C(O)--, O, --N(R.sup.10)--, --S(O).sub.2 N(R.sup.10)--, --N(R.sup.10)S(O).sub.2 --, or S(O).sub.m ;
- V is selected from:
- a) hydrogen,
- b) aryl,
- c) C.sub.1 -C.sub.20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and
- d) C.sub.2 -C.sub.20 alkenyl,
- provided that V is not hydrogen if A.sup.1 is S(O).sub.m and V is not hydrogen if A.sup.1 is a bond, n is 0 and A.sup.2 is S(O).sub.m ;
- W is imidazolyl;
- X is bond, --CH.sub.2 --, --C(.dbd.O)--, or --S(.dbd.O).sub.m --;
- Z is selected from:
- 1) a unsubstituted or substituted group selected from aryl, arylmethyl and arylsulfonyl, wherein the substituted group is substituted with one or more of the following:
- a) C.sub.1-4 alkyl, unsubstituted or substituted with:
- C.sub.1-4 alkoxy, NR.sup.4 R.sup.6, C.sub.3-6 cycloalkyl, aryl, HO, --S(O).sub.m R.sup.5, or --C(O)NR.sup.4 R.sup.6,
- b) aryl,
- c) halogen,
- d) OR.sup.4,
- e) NR.sup.4 R.sup.6,
- f) CN,
- g) NO.sub.2,
- h) CF.sub.3 ;
- i) --S(O).sub.m R.sup.5,
- j) --C(O)NR.sup.4 R.sup.6, or
- k) C.sub.3 -C.sub.6 cycloalkyl;
- and
- 2) unsubstituted C.sub.1-C.sub.6 alkyl, substituted C.sub.1 -C.sub.6 alkyl, unsubstituted C.sub.3 -C.sub.6 cycloalkyl or substituted C.sub.3 -C.sub.6 cycloalkyl, wherein the substituted C.sub.1 -C.sub.6 alkyl and substituted C.sub.3 -C.sub.6 cycloalkyl is substituted with one or two of the following:
- a) C.sub.1-4 alkoxy,
- b) NR.sup.4 R.sup.6,
- c) C.sub.3-6 cycloalkyl,
- d) --NR.sup.4 C(O)R.sup.6,
- e) HO,
- f) --S(O).sub.m R.sup.5,
- g) halogen, or
- h) perfluoroalkyl;
- aryl is independently selected from phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl and acenaphthyl;
- m is 0, 1 or 2;
- n is 0, 1, 2, 3 or 4;
- p is 0, 1, 2, 3 or 4;
- q is 1 or 2;
- r is 0 to 5, provided that r is 0 when V is hydrogen;
- t is 1;
- and
- u is 4 or 5;
- or a pharmaceutically acceptable salt thereof.
74 more elements
A compound which inhibits farnesyl-protein transferase which is:
- 4-1-(4-Cyanobenzyl)-5-imidazolylmethyl!-1-(3-chlorophenyl)-piperazine-2,3- dione
- (S)-5-n-butyl-4-1-(4-cyanobenzyl)-5-imidazolylmethyl!-1-(2,3-dimethylpheny l)-2,3-piperazinedione
- 4-1-(4-cyanobenzyl)-5-imidazolylmethyl!-1-(2,3-dimethylphenyl)-piperazine- 2,3-dione
- (S)-5-Benzyl-1-(4-cyanobenzyl)-5-imidazolylmethyl!-1-phenyl-2,3-piperazine dione
- (S)-4-1-(4-cyanobenzyl)-2-methyl-5-imidazolylmethyl!-5-(2-methyl-1-propyl) -1-3-(trifluoromethoxy)phenyl!-2,3-piperazinedione
- 4-1-(4-cyanobenzyl)-2-methyl-5-imidazolylmethyl!-1-phenylpiperazine-2,3-di one
- 1-(4-imidazolyl)-4-(2,3-dimethylphenyl)piperazine-2,3-dione
- 1-1-(4-cyanobenzyl)-5-imidazolyl!-4-(2,3-dimethylphenyl)piperazine-2,3-dio ne
- or a pharmaceutically acceptable salt or optical isomer thereof.
6 more elements
Dependencies are inferred from the claim text.